DaVita Inc.

DaVita’s Q1 2026 10-Q dedicates notable attention to its capital allocation strategy, particularly share repurchases. The company executed significant share repurchases (a company buying back its own stock from the open market) during the first quarter of 2026, acquiring 3,005 thousand shares at an average price of $133.70. This activity, detailed in Item 2, leaves an approximate dollar value of shares that may yet be purchased under existing programs totaling $1,756,319 thousand as of March 31, 2026. The consistent execution across January, February, and March, with 1,658 thousand, 522 thousand, and 825 thousand shares repurchased respectively, suggests a deliberate, rather than opportunistic, approach to managing outstanding equity. Such programs reflect management’s ongoing commitment to returning capital to shareholders, a common practice that can influence per-share metrics by reducing the total share count, though the filing does not elaborate on the specific rationale beyond Board authorizations.

The customary forensic accounting metrics, such as Beneish’s 1999 eight-ratio earnings-manipulation detector, Altman’s Z″ — a 1968 bankruptcy-distress index, and Piotroski’s F-Score, a 9-point fundamental strength scan, are not available for this filing. Similarly, the Fog Index — a readability score where 12 equals newspaper and 18+ suggests obfuscatory prose — is also absent from the provided data. This absence means the filing cannot be assessed for potential earnings manipulation signals, financial distress indicators, or the fundamental strength of its operations through these established quantitative frameworks. Consequently, this reading relies solely on the qualitative and quantitative data explicitly presented in the excerpts, without the benefit of these academically-derived benchmarks for comparative analysis or early warning signs.

Turning to the Consolidated Statements of Income in Item 7, DaVita reported an increase in total revenues, moving from $3,223,529 thousand in the three months ended March 31, 2025, to $3,415,548 thousand for the same period in 2026. This growth was primarily driven by dialysis patient service revenues, which rose from $3,102,993 thousand to $3,272,797 thousand year-over-year. Operating income also saw an improvement, reaching $481,892 thousand in Q1 2026, up from $438,937 thousand in Q1 2025, indicating an expansion of profitability before non-operating items. However, this top-line and operating income growth was accompanied by increased operating expenses, with patient care costs rising from $2,239,660 thousand to $2,342,257 thousand, and general and administrative expenses increasing from $374,090 thousand to $421,914 thousand. The concurrent rise in both revenues and expenses suggests a business operating with consistent activity levels, where debt expense also increased from $135,055 thousand to $145,131 thousand.

This forensic reading, constrained by the provided excerpts and the absence of key analytical scores, offers a snapshot of DaVita’s capital allocation and operational performance. The filing clearly communicates the company’s active share repurchase program and its ability to generate increased revenues and operating income year-over-year. However, without the Beneish M-Score, Altman Z″, Piotroski F-Score, or Fog Index, a deeper assessment of potential accounting risk, financial distress, fundamental quality, or the clarity of disclosure remains beyond the scope of this analysis. The information presented, while numerically specific regarding revenue and expense trends, does not provide the qualitative context or the quantitative red flags that these established forensic metrics are designed to uncover. Therefore, while the filing illustrates a company engaged in significant share repurchases and demonstrating top-line growth, it does not offer the comprehensive forensic insights typically derived from a full suite of analytical tools.